IP Library Patent Application 17167252
Patent Application
App. No. 17/167,252

Systems and Methods for Pesticide Detection

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/167,252
Abstract

This disclosure provides quantitative, rapid, and reliable LC-MS/MS methods for analyzing panels of pesticides and mycotoxins in various samples, including very hydrophobic and chlorinated compounds normally analyzed on a GC-MS/MS system. The methods can be carried out using a single instrument and can detect and quantify levels of the pesticides and mycotoxins that are well below action limits specified by U.S. states (e.g., California) and other countries (e.g., Canada) for these compounds in cannabis products.

Claims (29)

1 . A method of detecting a pesticide in a sample, the method comprising:

(a) ionizing at least a portion of the sample using an atmospheric chemical ionization (APCI) source to create a first ionized sample stream; and

(b) detecting, using a triple quadrupole mass spectrometer, a first MRM transition in the first ionized sample stream, wherein the first MRM transition is selected from the group consisting of 439.8>35.1 (chlordane) and 441.8>35.1 (chlordane).

2 . The method of claim 1 , further comprising:

(c) ionizing at least a portion of the sample using an electrospray ionization (ESI) source to create a second ionized sample stream; and

(d) detecting a second MRM transition in the second ionized sample stream.

3 . The method of claim 2 , wherein the second MRM transition is an MRM transition of a pesticide, wherein the pesticide is selected from the group consisting of abamectin, acephate, acequinocyl, acetamiprid, aldicarb, atrazine, azoxystrobin, bifenazate, bifenthrin, boscalid, captan, carbaryl, carbofuran, chlorantraniliprole, chlorfenapyr, chlorpyrifos, cinerin-I, cinerin-II, clofentezine, coumaphos, cyfluthrin, cypermethrin, daminozide, diazinon, dichlorvos, dimethoate, dimethomorph, ethoprophos, etofenprox, etoxazole, fenhexamid, fenoxycarb, fenpyroximate, fipronil, flonicamid, fludioxonil, hexythiazox, imazalil, imidacloprid, jasmolin-I, jasmolin-II, kresoxim-methyl, malathion, metalaxyl, methiocarb, methomyl, mevinphos, myclobutanil, naled, n-octyl bicycloheptene dicarboximide (MGK-264), oxamyl, paclobutrazol, parathion methyl, permethrin, phosmet, piperonyl butoxide, prallethrin, propiconazole, propoxur, pyrethrin-I, pyrethrin-II, pyridaben, spinetoram, spinosyn A, spinosyn D, spiromesifen, spirotetramat, spiroxamine, tebuconazole, thiachloprid, thiamethoxam, thiophanate methyl, and trifloxystrobin.

4 . The method of claim 1 , wherein the first ionized sample stream is obtained from a cannabis sample.

5 . The method of claim 2 , further comprising:

(e) detecting a third MRM transition in the second ionized sample stream, wherein the third MRM transition is associated with a mycotoxin selected from the group consisting of mycotoxin B1, mycotoxin B2, mycotoxin G1, mycotoxin G2, and ochratoxin A.

6 . The method of claim 3 , further comprising:

(e) detecting a third MRM transition in the second ionized sample stream, wherein the third MRM transition is associated with a mycotoxin selected from the group consisting of mycotoxin B1, mycotoxin B2, mycotoxin G1, mycotoxin G2, and ochratoxin A.

7 . The method of claim 2 , wherein the second MRM transition is selected from the group consisting of 402.2>343.1 (acequinocyl) and 402.2>189 (acequinocyl).

8 . The method of claim 2 , wherein the second MRM transition is selected from the group consisting of 316.9>263.9 (captan), 316.9>235.9 (captan), 318.9>265.9 (captan), and 318.9>237.9 (captan).

9 . The method of claim 2 , wherein the second MRM transition is selected from the group consisting of 407.0>59.1 (chlorfenapyr), 424.0>59.1 (chlorfenapyr), and 426.0>59.1 (chlorfenapyr).

10 . The method of claim 2 , wherein the second MRM transition is 361.2>213.0 (cinerin-II).

11 . The method of claim 2 , wherein the second MRM transition is 453.1>193.0 (cyfluthrin).

12 . The method of claim 2 , wherein the second MRM transition is 435.1>193.1 (cypermethrin).

13 . The method of claim 2 , wherein the second MRM transition is selected from the group consisting of 161.1>44.0 (daminozide) and 161.1>45.0 (daminozide).

14 . The method of claim 2 , wherein the second MRM transition is 375.2>213.0 (jasmolin II).

15 . The method of claim 2 , wherein the second MRM transition is selected from the group consisting of 380.8>127.0 (naled) and 382.8>127.0 (naled).

16 . The method of claim 2 , wherein the second MRM transition is selected from the group consisting of 344.1>69.0 (propiconazole) and 344.1>161.0 (propiconazole).

17 . The method of claim 1 , further comprising:

(c) detecting a second MRM transition in the first ionized sample stream, wherein the second MRM transition is selected from the group consisting of 275.8>35.1 (pentachloronitrobenzene), 273.8>35.1 (pentachloronitrobenzene), and 275.8>201.9 (pentachloronitrobenzene).

18 . The method of claim 1 , further comprising:

(c) detecting a second MRM transition in the first ionized sample stream, wherein the second MRM transition is selected from the group consisting of 216.8>35.0 (etridiazole) and 218.8>35.0 (etridiazole).

19 . The method of claim 1 , further comprising:

(c) detecting a second MRM transition in the first ionized sample stream, wherein the second MRM transition is selected from the group consisting of 346.9>79.0 (chlorfenapyr) and 348.9>81.0 (chlorfenapyr).

20 . The method of claim 1 , wherein the APCI source uses a nebulizing gas selected from the group consisting of air, nitrogen, carbon dioxide, and argon.

Assignments (4)
CORRECTIVE COVERSHEET TO CORRECT EXECUTION DATE REEL/FRAME: 063170/0730 Recorded Nov 30, 2023
From: PERKINELMER HEALTH SCIENCES INC.
To: PERKINELMER U.S. LLC
Reel/Frame 065728/0162 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2023
From: PERKINELMER HEALTH SCIENCES INC.
To: PERKINELMER U.S. LLC
Reel/Frame 063170/0730 →
SECURITY INTEREST Recorded Mar 13, 2023
From: PERKINELMER U.S. LLC
To: OWL ROCK CAPITAL CORPORATION
Reel/Frame 066839/0109 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: DALMIA, AVINASH
To: PERKINELMER HEALTH SCIENCES, INC.
Reel/Frame 055146/0058 →